The fair value of the Company's available-for-sale investments as of and were million and million, respectively. The decrease was due

 

Inventories consist of (in thousands):

 

		June 30,
		2019				201 8
Raw materials		$	40,913			$	30,956
Finished goods (1)			53,376				54,692
Inventories, net		$	94,289			$	85,648

 

() Finished goods inventory of is included within other long-term assets in the Balance Sheet as it forecasted to be sold after the months subsequent to the consolidated balance sheet date.  

 

 

Property and equipment consist of (in thousands):

 

		June 30,
		201 9				201 8
Cost:
Land		$	7,065			$	7,065
Buildings and improvements			175,019				170,110
Machinery, equipment and other			124,233				107,625
Property and equipment			306,317				284,800
Accumulated depreciation and amortization			(152,278	)			(139,452	)
Property and equipment, net		$	154,039			$	145,348

Intangibles assets were comprised of the following (in thousands):

 

							June 30,
		Useful Life (years)					201 9				201 8
Developed technology		9	-	15			$	435,679			$	305,303
Trade names		2	-	20				147,296				89,608
Customer relationships		7	-	16				214,320				212,228
Patents			10					2,133				1,401
Intangible assets								799,428				608,540
Accumulated amortization								(219,999	)			(162,208	)
Intangibles assets, net							$	579,429			$	446,332

 

Changes to the carrying amount of net intangible assets consist of (in thousands):

 

		June 30,
		201 9				201 8
Beginning balance		$	446,332			$	452,042
Acquisitions (Note 4)			191,956				40,673
Other additions			633				908
Amortization expense			(58,715	)			(47,076	)
Currency translation			(777	)			(215	)
Ending balance		$	579,429			$	446,332

 

Amortization expense related to technologies included in cost of sales was  million, million, and million in fiscal and respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was  million, million, and million, in fiscal and respectively.

 

The estimated future amortization expense for intangible assets as of is as follows (in thousands):

 

2020		$	59,905
2021			59,557
2022			57,905
2023			56,031
2024			53,464
Thereafter			292,567
Total		$	579,429

 

		Protein Sciences				Diagnostics & Genomics				Total
June 30, 2017		$	331,789			$	247,237			$	579,026
Acquisitions (Note 4)			16,186				2,910				19,096
Currency translation			(56	)			(176	)			(232	)
June 30, 2018		$	347,918			$	249,972			$	597,890
Acquisitions (Note 4)			30,939				105,362				136,301
Currency translation			(1,450	)			(74	)			(1,524	)
June 30, 2019		$	377,407			$	355,260			$	732,667

Other assets consist of (in thousands):

 

		June 30,
		201 9				201 8
Investments		$	-			$	2,606
Other			5,668				2,660
Other long-term assets		$	5,668			$	5,266

 

As of the Company had  million of other assets compared to million as of The increase was attributable to finished goods inventory of million included within other long-term assets in the Balance Sheet as it forecasted to be sold after the months subsequent to the consolidated balance sheet date. This increase was partially offset by the reduction in investments related to our purchase of the outstanding shares of B-MoGen discussed in note and the reclassification of the amounts held in escrow from our Astute investment classified as a long-term asset as of to a short-term asset as of as we are expected to receive the final proceeds within the next months. 

 

 

Supplemental cash flow information was as follows (in thousands):

 

		Year Ended June 30,
		201 9				201 8				201 7
Income taxes paid		$	36,814			$	35,076			$	42,900
Interest paid			21,497				9,844				7,452
Non-cash activities:
Acquisition-related liabilities (1)			12,600				1,396				32,856